The pharmaceutical behemoths Pfizer and Astellas have revealed ground-breaking findings from a significant clinical trial that demonstrate how their combination therapy dramatically increases survival for patients with muscle-invasive bladder cancer who are unable to receive conventional chemotherapy. This is a historic development for the treatment of bladder cancer.
When given both before and after surgery, PADCEVTM (enfortumab vedotin) and KEYTRUDATM (pembrolizumab) result in clinically meaningful and statistically significant improvements in event-free survival and overall survival when compared to surgery alone, according to the Phase 3 EV-303 clinical trial.
Read More: Pfizer and Astellas Announce Landmark Survival Benefit with XTANDI in Prostate Cancer Trial
The EV-303 Clinical Trial Design
For this difficult patient group, the EV-303 study offers a thorough method of assessing novel therapeutic approaches. An open-label, randomized, three-arm, controlled Phase 3 trial is now underway to compare various treatment modalities for MIBC patients who have either declined or are ineligible for cisplatin-based chemotherapy.
Structure of the Trial
- Arm A: Keytruda alone as a neoadjuvant and adjuvant
- Arm B: The current standard of therapy is surgery alone.
- Arm C: Combination of neoadjuvant and adjuvant PADCEV with KEYTRUDA.
The primary goal measures the time from randomization to disease progression, surgical complications, cancer recurrence, or death, and compares event-free survival between the combination therapy arm and surgery alone. Pathologic full response rates and overall survival are important secondary objectives.
Clinical Outcomes
The experiment accomplished its main goals with outstanding outcomes in the first interim efficacy analysis.
- Improvement in event-free survival (the main outcome) that is statistically significant
- Notable increase in overall survival, which is a crucial secondary objective.
- Pathologic full response rate achievement (an extra secondary objective)
- The safety profiles for KEYTRUDA monotherapy and PADCEV with KEYTRUDA stayed true to their established safety features.
Regulatory and Development Timeline
In addition to discussing the results with international health authorities for possible regulatory filings, the firms intend to submit these results for presentation at an upcoming medical congress. This could lead to increased approvals for the combo therapy in the earlier-stage bladder cancer context.
Furthermore, the combination is being assessed in MIBC patients who are eligible for cisplatin in the ongoing EV-304 Phase 3 clinical trial (also called KEYNOTE-B15), which could broaden the patient base for treatment.
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
